@article {Tian20210108, author = {Ye Tian and Qiang Li and Yuan Pan}, title = {Prospective study of the effect of ERAS on postoperative recovery and complications in patients with gastric cancer}, elocation-id = {20210108}, year = {2021}, doi = {10.20892/j.issn.2095-3941.2021.0108}, publisher = {Cancer Biology \& Medicine}, abstract = {Objective: To study the efficacy of the enhanced recovery after surgery (ERAS) program on postoperative recovery and complications in patients with gastric cancer.Methods: Eighty patients in the perioperative period with radical gastrectomy were enrolled and randomly divided into 2 groups, the ERAS group and the non-ERAS group. The differences between the 2 groups in terms of postoperative recoveries and complications rate were determined. According to the body mass index (BMI) level, the ERAS group was divided into 2 subgroups, namely group A (BMI \< 28 kg/m2, n = 16) and group B (BMI >= 28 kg/m2, n = 24). The non-ERAS group was also divided into group C (BMI \< 28 kg/m2, n = 18) and group D (BMI >= 28 kg/m2, n = 22). The recovery and complications of each group were then determined.Results: The postoperative length of stay and visual analogue scale pain score were less in the ERAS group than the non-ERAS group (P \< 0.05). Time to first postoperative exhaustion, first postoperative defecation, returning leukocyte count to normal, and stopping intravenous nutrition were significantly shorter in the ERAS group (n = 40), compared to the non-ERAS group (n = 40, all P \< 0.05). The incidence of postoperative lower extremity intramuscular venous thrombosis was significantly higher in group D than in group B (χ2 = 4.800, P = 0.028). In addition, the incidence of lower extremity intermuscular venous thrombosis and lung infection in group D was higher than those in other groups.Conclusions: The perioperative ERAS program was associated with faster recovery in patients undergoing radical gastrectomy. For patients with higher BMI (BMI >= 28 kg/m2), the use of the perioperative ERAS program was more advantageous.}, issn = {2095-3941}, URL = {https://www.cancerbiomed.org/content/early/2022/07/15/j.issn.2095-3941.2021.0108}, eprint = {https://www.cancerbiomed.org/content/early/2022/07/15/j.issn.2095-3941.2021.0108.full.pdf}, journal = {Cancer Biology \& Medicine} }